WO2003035619A8 - Inhibiteurs de la tyrosine kinase - Google Patents
Inhibiteurs de la tyrosine kinaseInfo
- Publication number
- WO2003035619A8 WO2003035619A8 PCT/US2002/033962 US0233962W WO03035619A8 WO 2003035619 A8 WO2003035619 A8 WO 2003035619A8 US 0233962 W US0233962 W US 0233962W WO 03035619 A8 WO03035619 A8 WO 03035619A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- tyrosine kinase
- kinase inhibitors
- present
- receptor
- Prior art date
Links
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34300001P | 2001-10-25 | 2001-10-25 | |
US60/343,000 | 2001-10-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003035619A1 WO2003035619A1 (fr) | 2003-05-01 |
WO2003035619A8 true WO2003035619A8 (fr) | 2003-07-03 |
Family
ID=23344243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/033962 WO2003035619A1 (fr) | 2001-10-25 | 2002-10-21 | Inhibiteurs de la tyrosine kinase |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2003035619A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8946278B2 (en) | 2007-02-07 | 2015-02-03 | Glaxosmithkline Llc | Inhibitors of AkT activity |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1926996B1 (fr) | 2005-09-20 | 2011-11-09 | OSI Pharmaceuticals, Inc. | Marqueurs biologiques prédictifs d'une réaction anticancéreuse aux inhibiteurs kinase du récepteur du facteur de croissance 1 analogue à l'insuline |
EP2400985A2 (fr) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Thérapie anti-cancer combinée |
US20110171124A1 (en) | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
EP2401613A2 (fr) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation |
JP2012519281A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
WO2010099138A2 (fr) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation |
US20100316639A1 (en) | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
AU2011223643A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EP2542893A2 (fr) | 2010-03-03 | 2013-01-09 | OSI Pharmaceuticals, LLC | Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1 |
EP2544672A1 (fr) | 2010-03-09 | 2013-01-16 | OSI Pharmaceuticals, LLC | Thérapie anticancéreuse combinatoire |
WO2012116040A1 (fr) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de la kinase du récepteur du facteur de croissance 1 analogue à l'insuline dans le carcinome hépatocellulaire |
EP2702173A1 (fr) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer |
WO2013152252A1 (fr) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Polythérapie antinéoplasique |
WO2014134202A1 (fr) | 2013-02-26 | 2014-09-04 | Triact Therapeutics, Inc. | Cancérothérapie |
WO2015035410A1 (fr) | 2013-09-09 | 2015-03-12 | Triact Therapeutic, Inc. | Traitement du cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010108063A (ko) * | 1998-12-31 | 2001-12-07 | 수젠, 인크. | 단백질 인산화 효소의 조절 및 암의 화학적 치료를 위한3-헤테로아릴리데닐-2-인돌리논 화합물 |
-
2002
- 2002-10-21 WO PCT/US2002/033962 patent/WO2003035619A1/fr not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8946278B2 (en) | 2007-02-07 | 2015-02-03 | Glaxosmithkline Llc | Inhibitors of AkT activity |
Also Published As
Publication number | Publication date |
---|---|
WO2003035619A1 (fr) | 2003-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004014300A3 (fr) | Inhibiteurs de la tyrosine kinase | |
WO2004014851A3 (fr) | Inhibiteurs de tyrosine kinases | |
WO2003035615A3 (fr) | Inhibiteurs de tyrosine kinase | |
WO2003035616A3 (fr) | Inhibiteurs de la tyrosine kinase | |
WO2003035619A8 (fr) | Inhibiteurs de la tyrosine kinase | |
WO2003035614A3 (fr) | Inhibiteurs de la tyrosine kinase | |
WO2004031401A3 (fr) | Nouveaux inhibiteurs de tyrosine kinases | |
WO2002046183A3 (fr) | Composes de pyrroline substitues par l'indazolyle comme inhibiteurs de kinase | |
CA2400447A1 (fr) | Inhibiteurs de kinases | |
AU2001241798A1 (en) | 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors | |
WO2004096795A3 (fr) | Inhibiteurs de la kinase c-fms | |
WO2000043373A3 (fr) | Inhibiteurs de kinase | |
WO2006050109A3 (fr) | Nouveaux inhibiteurs de kinase | |
WO2001019828A3 (fr) | Inhibiteurs de kinase utilises comme agents therapeutiques | |
WO2000002576A3 (fr) | Egf-genistein utilise pour la prevention de la restenose | |
MY141739A (en) | Substituted quinazoline derivatives as inhibitors of aurora kinases | |
EP0766676A4 (fr) | Composes et procede destines a inhiber la phosphodiesterase iv | |
AU2001241927A1 (en) | Inhibitors of p38-alpha kinase | |
WO2001060814A3 (fr) | Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole | |
WO2004009597A3 (fr) | Pyrazolopyrimidines en tant qu'inhibiteurs de kinases | |
AU2001288374A1 (en) | Substituted oxindole derivatives as tyrosine kinase inhibitors | |
WO2006047479A3 (fr) | Inhibiteurs de c-fms kinase | |
WO2001056573A8 (fr) | Utilisation d'inhibiteurs de cox-2 en tant qu'agents procinetiques gastriques | |
EP1390052A4 (fr) | Inhibition de la kinase jun | |
AU5215700A (en) | Substituted indolinone as tyrosine kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 18/2003 UNDER (22) REPLACE "23 OCTOBER 2002 (23.10.2002)" BY "21 OCTOBER 2002 (21.10.2002)" |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |